Bridge To Life

Executive Summary

Bridge To Life Ltd. is a global medical device company dedicated to advancing organ preservation and perfusion technologies for transplantation. Founded in 2005, the company has established a strong foothold with its Belzer UW® cold storage solution, considered the gold standard in the field, and its proprietary VitaSmart™ hypothermic oxygenated perfusion (HOPE) system, designed to improve organ viability and transplant outcomes. Serving organ procurement organizations and transplant centers worldwide, Bridge To Life addresses the critical need for better preservation methods in an era of increasing organ demand and transplant waitlists. The company's portfolio aims to extend organ preservation time, reduce complications, and ultimately increase the number of successful transplants. With a private status and no disclosed financials, Bridge To Life operates in a niche but essential segment of medical devices, poised to benefit from growing adoption of perfusion technology and regulatory support for innovations that enhance transplant success rates.

Upcoming Catalysts (preview)

• Q4 2026FDA approval of VitaSmart HOPE system for expanded indications60% success
• Q2 2026Publication of pivotal clinical trial results demonstrating improved graft survival70% success
• Q3 2026Strategic distribution partnership for Asia-Pacific market entry50% success